Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries

Ekaterina V. Kurbatova, Tracy Dalton, Julia Ershova, Thelma Tupasi, Janice Campos Caoili, Martie Van Der Walt, Charlotte Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Laura E. Via, Heejin Kim, Somsak Akksilp, Boris Y. Kazennyy, Grigory V. Volchenkov, Ruwen Jou, Kai Kliiman, Olga V. Demikhova, J. Peter Cegielski

Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

8 Citas (Scopus)

Resumen

Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5–6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2–4) drugs; 26% retained susceptibility to <2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens.

Idioma originalInglés
Páginas (desde-hasta)977-983
Número de páginas7
PublicaciónEmerging Infectious Diseases
Volumen21
N.º6
DOI
EstadoPublicada - 2015

Nota bibliográfica

Publisher Copyright:
© 2015 Centers for Disease Control and Prevention (CDC). All rights reserved.

Huella

Profundice en los temas de investigación de 'Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries'. En conjunto forman una huella única.

Citar esto